AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $40.08.

ANAB has been the subject of a number of analyst reports. UBS Group raised their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of AnaptysBio in a report on Monday. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, Wells Fargo & Company cut their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th.

AnaptysBio Trading Up 0.1 %

Shares of ANAB stock opened at $16.08 on Friday. The business’s 50-day moving average price is $16.87 and its 200-day moving average price is $26.69. AnaptysBio has a 12 month low of $12.51 and a 12 month high of $41.31. The firm has a market capitalization of $489.30 million and a price-to-earnings ratio of -2.64.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, sell-side analysts predict that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average cost of $12.95 per share, with a total value of $86,065.70. Following the transaction, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in AnaptysBio in the third quarter worth $49,000. nVerses Capital LLC raised its stake in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares during the last quarter. Point72 DIFC Ltd boosted its position in AnaptysBio by 680.5% during the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 5,342 shares during the period. Finally, SG Americas Securities LLC boosted its position in AnaptysBio by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 4,231 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.